Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

BACKGROUND: Solitomab is a novel bispecific single-chain antibody which targets EpCAM on tumor cells and also contains a CD3 binding region. We evaluated in vitro activity of solitomab against primary chemo-resistant epithelial ovarian carcinoma cell lines as well as malignant cells in ascites. METH...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer
Главные авторы: English, Diana P., Bellone, Stefania, Schwab, Carlton L., Roque, Dana M., Lopez, Salvatore, Bortolomai, Ileana, Cocco, Emiliano, Bonazzoli, Elena, Chatterjee, Sudeshna, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E., Rutherford, Thomas J., Santin, Alessandro D.
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4304922/
https://ncbi.nlm.nih.gov/pubmed/25251053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29062
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы